B. Santos

In vitro percutaneous absorption and metabolism of ozenoxacin in excised human skin.

S. Gropper, Jordi Ortiz, B. Santos, 2014, Future microbiology.

Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure

R. Antonijoan, M. Puntes, M. Ballester, 2015, Drug design, development and therapy.

A BIOAVAILABILITY/BIOEQUIVALENCE AND PHARMACOKINETIC STUDY OF TWO ORAL DOSES OF TORASEMIDE (5 AND 10 mg): PROLONGED‐RELEASE VERSUS THE CONVENTIONAL FORMULATION

M. Puntes, M. Ballester, M. Barbanoj, 2009, Clinical and experimental pharmacology & physiology.

Comparison of repeated‐dose pharmacokinetics of prolonged‐release and immediate‐release torasemide formulations in healthy young volunteers

R. Antonijoan, M. Ballester, I. Gich, 2009, Fundamental & clinical pharmacology.

Systemic bioavailability, safety and tolerability of topical ozenoxacin in healthy adult volunteers.

S. Gropper, N. Albareda, S. Febbraro, 2014, Future microbiology.

Systemic bioavailability and safety of twice-daily topical ozenoxacin 1% cream in adults and children with impetigo.

S. Gropper, Dawie Kruger, A. Cepero, 2014, Future microbiology.

Skin tissue exposure of once- versus twice-daily topical ozenoxacin 2% cream: a Phase I study in healthy volunteers.

S. Gropper, N. Albareda, S. Febbraro, 2014, Future microbiology.

A BIOAVAILABILITY/BIOEQUIVALENCE AND PHARMACOKINETIC STUDY OF TWO ORAL DOSES OF TORASEMIDE (5 AND 10 mg): PROLONGED‐RELEASE VERSUS THE CONVENTIONAL FORMULATION

M. Puntes, M. Ballester, A. Guglietta, 2009, Clinical and experimental pharmacology & physiology.